Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.

Emory University's pioneering work with a class of small molecules known as JAK (janus kinase) inhibitors continues to show how HIV might be cured ...

Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.